Giant vascular eccrine spiradenoma: the first case in the scrotum and review of the literature

Zan Li, Gang Li, Xin Jiang and Xiaoming Fu

Abstract

Background: Giant vascular eccrine spiradenoma is a rare variant of eccrine spiradenoma. It is different from the eccrine spiradenoma in its larger size and greater degree of vascularity. It is often clinically confused with a vascular or malignant tumor.

Case presentation: Here, we report a case of a 67-year-old man who presented with a tumor in the scrotum. The tumor had begun as a small nodule and had grown slowly over time. Surgical excision and pathological examination revealed that the lesion was a giant vascular eccrine spiradenoma.

Conclusion: This study reports the first case of giant vascular eccrine spiradenoma in the scrotum.

Keywords: Eccrine spiradenoma, Giant vascular eccrine spiradenoma, Scrotum mass, Histopathology, Immunohistochemistry

Background
Eccrine spiradenoma, which was first described in detail by Kersting and Helwig in 1956, is an uncommon benign skin adnexal tumor originating from sweat glands [1]. It commonly arises in the head, neck, trunk and extremities as a dermal or subcutaneous nodule or papule and is sometimes accompanied with pain and tenderness [2].

Giant vascular eccrine spiradenoma is a rare highly vascular variant of eccrine spiradenoma, that might be mistaken for a vascular lesion or malignant tumor due to its florid vascularity and hemorrhagic features. The gross morphology of the tumor is not distinctcttherefore, the clinical diagnosis of giant vascular eccrine spiradenoma is very difficult, and biopsy is required for an accurate diagnosis.

Case presentation
Clinical history
Our patient was a 67-year-old male who presented with a solitary mass in the scrotum. The lesion began as a small nodule that slowly increased in size over the past 6 years. The patient had no family history or traumatic history. He complained of no symptoms other than mild tenderness. Ultrasonography indicated a well-circumscribed oval mass in the dermis of the scrotum. Urological and dermatological examination revealed a single tender, skin-colored, firm dermis mass of the scrotum. The lesion was surgically excised and sent for histopathological examination.

Pathological findings
Gross examination of the resected specimen showed that the skin surface of the scrotum was not different from other areas. The mass, which was located in the dermis of the scrotum, was approximately 3.2 × 2.3 cm in size (Fig. 1a). The cut surface of the mass was hemorrhagic (Fig. 1b).
Histopathologic examination showed several sharply defined basophilic tumor nodules in the dermis, extending into the subcutis without any connection to the overlying epidermis. The overlying epidermis was almost intact and the surrounding connective tissue was normal. The tumor nodules comprising round-to-oval or basaloid cells arranged in acinar, sheet, cord-like, and trabecular patterns, were surrounded by a thin layer of fibrous tissue. At high magnification, three types of cells were observed in the nodules (Fig. 2a). The first were large cells with pale to slightly basophilic cytoplasm and vesicular nuclei. The nuclear membrane was thin, and the nucleolus was evident. The second were basaloid cells that surrounded the large cells. The basaloid cells were small with hyperchromatic nuclei. The third were spindle myoepithelial cells. Cytological atypia, mitoses and necrosis were not observed. Scattered lymphocytes were observed among the tumor cells and certain tubular differentiations. The stroma showed numerous dilated vascular spaces containing red blood cells and extensive hemorrhage (Fig. 2b).

Immunohistochemically, the large epithelial cells were strongly positive for CK, CK7 and CK8 (Fig. 3a) and negative for P63. The small basaloid cells in the outer layer were positive for P63 (Fig. 3b) and negative for SMA. The myoepithelial cells among or around the tubules were positive for S-100 (Fig. 3c) and SMA (Fig. 3d).

Thus, the diagnosis of giant vascular eccrine spiradenoma was supported by the histologic features and immunohistochemical findings.

**Discussion**

Eccrine spiradenoma is a benign adnexal tumor that usually appears as a small, solitary, painful and gray-pink nodule and occurs equally in both males and females. Multiple eccrine spiradenoma is an extremely rare presentation comprising less than 2% of all cases [3]. Multiple lesions have been reported to occur either in a random fashion or in linear, nevoid, blaschkoid and zosteriform patterns [4].

Lauret et al. [5] first introduced the appellation “giant eccrine spiradenoma” in 1977. Jamshidi et al. [6]
reported tumors as large as 12 cm in size. Giant vascular eccrine spiradenoma, a rare variant of eccrine spiradenoma, was first described by Cotton et al. in 1986 [7]. They reported two cases of large eccrine spiradenoma with a marked degree of vascularity. The giant vascular variant is different from eccrine spiradenoma by its larger size (diameter of > 2 cm) and high vascularity. The vascularity and hemorrhagic features may result in an erroneous diagnosis by both clinicians and pathologists.

Following the two cases mentioned earlier, 12 cases of giant vascular eccrine spiradenoma have been reported in the literature. The summarization of the previously reported cases was described in Table 1. Most of the reported cases have occurred in individuals over 49 years of age; one case each occurred in men aged 41 [8] and 31 [9]. There is no significant difference in the incidence between men and women. In terms of duration, the shortest lasted 3 to 4 months, and the longest was 30 years [10]. The literature reports lesion sizes varying from 2 cm to 7 cm. The reported sites include the head, trunk and limbs. However, giant vascular eccrine spiradenoma in the scrotum has not been reported.

Table 1: Summary of cases of giant vascular eccrine spiradenoma

| Year | Age/ Sex | Location | Size(cm) | Duration | Symptom | Clinical Diagnosis | Unique Features |
|------|----------|----------|----------|----------|---------|--------------------|-----------------|
| 1986 | 74/M     | Abdomen  | 5        | 2 years  | Not mentioned | Angiosarcoma or Malignant melanoma | Ulcerated brown mass |
| 1986 | 84/F     | Scalp    | 2        | 3–4 months | Not mentioned | Sebaceous cyst | Cystic lesion and blood-stained discharge |
| 1988 | 63/F     | Thigh    | 3.5 × 1.5 | Unknown | Not mentioned | Venous thrombosis | None |
| 1998 | 60/M     | Hypochondrim | 3–4 | 5 years | No pain | Angioma or thrombosis | Violaceous, ulcerated and bleeding lesion |
| 2006 | 56/F     | Back     | 2        | 3 years | Paroxysmal pain | Angiolipoma or neuroma | Erythematous to violaceous hemispheric firm nodule |
| 2009 | 76/M     | Shoulder | 5 × 3.4 × 2.6 | 3 years | No pain | Not mentioned | Pale red pedunculated tumor with bleeding |
| 2011 | 81/M     | Forearm  | 1.47 × 2.57 × 2.86 | 3 years | Painful on palpation | Not mentioned | Blue nodule with haemorrhage |
| 2011 | 49/F     | Arm      | 2.5 × 2.5 | 10 years | Asymptomatic | Vascular malformation | Slightly bluish mass with the overlying intact skin |
| 2013 | 52/F     | Arm      | 3.5 × 2.2 | 10 years | No pain or tenderness | Calcifying epithelioma | Bluish-red nodule |
| 2014 | 79/M     | Chest    | 7 × 7 × 6 | 30 years | No pain or tenderness | Chronic expanding hematoma | Dark brown dome-shaped tumor |
| 2014 | 31/M     | Chest    | 2.5 × 2.5 | 1 year | No abnormal findings | Hemangioma | Grey brown firm nodule ulceration, bleeding |
| 2015 | 54/F     | Arm      | 2.3 × 2 × 2.6 | for years | Hard to palpation | Hemangioma | Reddish, dome-shaped lesion, ulcerated, bleeding |
| 2017 | 41/M     | Leg      | 3.5 × 3.0 | 7 years | Extremely painful | Malignant tumor | Violaceous, ulcerated nodular |
| 2018 | 68/M     | Back     | 6.0 × 3.4 | 2 years | Slightly tenderness | Angiolipoma or cyst | Infiltrative growth pattern |
Most reported giant vascular eccrine spiradenomas appeared as deep dermis or subcutaneous solitary tumors, the surface of which showed red, gray, purple, blue, or pink color. The skin over the tumor can be smooth, ulcerated or bleeding. Yamakoshi et al. [11] reported a patient with giant vascular eccrine spiradenoma on his shoulder, where there was not enough growth space and the tumor formed a giant pedunculated mass.

The composition and differentiation of giant vascular eccrine spiradenoma are still debated. It is generally believed that the tumors are composed of two types of cells, large pale cells situated in the center and small basaloïd cells located in the periphery [12, 13]. However, some scholars have offered different conclusions. Ko et al. [14] and Corey et al. [15] described the immunohistochemical characteristics of giant vascular eccrine spiradenoma and arrived at similar conclusions. They found that giant vascular eccrine spiradenoma was typically composed of three types of cells: epithelial cells (CK+/CK7), small basal cells (p63+/SMA−), and myoepithelial cells (p63+/SMA+). The differentiation of myoepithelial cells can also be identified by positive staining for S-100 [16–18]. The results of our study are consistent with their conclusions. The immunohistological findings support the hypothesis that giant vascular eccrine spiradenoma originate from the eccrine glands and differentiate toward the secretory portion of the eccrine secretory coil [14, 15]. Electron microscopy also supports an eccrine origin for these lesions [7]. However, several authors have suggested that eccrine spiradenoma may be of apocrine origin [19, 20]. First, eccrine spiradenoma can coexist with appendage tumors, such as cylindroma, trichoepithelioma, and trichoblastoma, which are thought to originate from the apocrine gland [21, 22]. Second, eccrine spiradenoma occasionally exhibits histological features of apocrine secretion [23]. In any case, the basic theory is that the tumor originates from the secretory cells of sweat glands.

The considerable degree of vascularization is an unusual feature of giant vascular eccrine spiradenoma. At present, there are two explanations for the marked vascularity. One is that giant vascular eccrine spiradenoma arises from a highly vascular region of the normal sweat gland [7, 15]. Some scholars observed an afferent vessel of the tumor with drainage into the basilic vein supplied on MRI, so they presumed the tumor was vascular in origin [24]. Another view is that the vascular component is the result of a degeneration of the tumor stroma during the process of growing and aging [25]. We are inclined to support the former view. According to previous reports, the course of giant vascular eccrine spiradenoma varies from 3 months to 30 years, and all of these cases showed high vascularization. The common type of eccrine spiradenomas lasted for 15–30 years, but no obvious vascularization was observed [26–28]. It is thus clear that the duration of the disease is not directly related to the vascularization of the tumor.

The differential diagnosis of giant vascular eccrine spiradenoma is very important, and a variety of clinical diagnoses, including chronic expanding hematoma [10], calcifying epithelioma [29], angiolipoma or neuroma [14], desmoid [30], angiomatosus lesion or thrombosis [31], angiosarcoma [7], etc., could be erroneously made. Although malignant eccrine spiradenomas have been previously reported [32, 33], no malignant giant vascular eccrine spiradenoma has been described in the literature to date. Corey et al. [15] reported a case of giant vascular eccrine spiradenoma that showed an irregular infiltrative growth pattern into the surrounding pseudocapsule. Despite architectural atypia, they classified their case as a benign tumor because of the low proliferative index of Ki-67 staining and lack of mitotic figures. They also pointed out that the patient will be closely followed up in the future.

According to previous literature and our case, we summarized the clinical and pathological features of giant vascular eccrine spiradenoma as follows. Age: Most patients were older than 49 years, but one case each occurred in men aged 41 and 31. Location: All reported cases were located on the trunk or limbs except one on the scalp, and our case occurred in the scrotum. Gross appearance: The lesions presented as well-defined solitary mass larger than 2 cm in diameter and exhibited spontaneous hemorrhage and may be painful. Histological findings: Tumors usually contain three types of cells and dense dilated vasculature.

Our patient showed no recurrence one year after the operation. It is crucial to take giant vascular eccrine spiradenoma into consideration when diagnosing scrotal subcutaneous lesions. The principle of treatment for giant vascular eccrine spiradenoma is complete surgical excision with clear margins. Postoperative follow-up is important to detect recurrence.

Conclusions
In summary, we have reported the first case of giant vascular eccrine spiradenoma in the scrotum. It should be taken into account in the differential diagnosis of scrotal tumors.

Abbreviations
CK7: Cytokeratin7; CK8: Cytokeratin8; ES: Eccrine spiradenoma; GVES: Giant vascular eccrine spiradenoma; HE: Hematoxylin Eosin; SMA: Smooth muscle actin

Acknowledgements
Not applicable.
Li et al. Diagnostic Pathology  (2021) 16:37
Page 5 of 5

Authors’ contributions
ZL: performed the histological and immunohistochemical evaluation as well as wrote the manuscript. GL and XJ: performed the histological and immunohistochemical evaluation. XM: edited and reviewed the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (grant number. 81400572), and the Natural Science Foundation of Chongqing (grant number. cstc2017jcyjA0093).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors consent to the publication of the manuscript in Diagnostic Pathology.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Pathology, Chongqing General Hospital, 400013, ;2 College of Stomatology, Chongqing Medical University, Songshi Bei Road 426, Yubei District, 401147 Chongqing, China.

Received: 18 March 2020 Accepted: 9 February 2021
Published online: 30 April 2021

References
1. Kersting DW, Helwig EB. Eccrine spiradenoma. AMA Arch Derm. 1956;73:190–227.
2. Mambo NC. Eccrine spiradenoma: clinical and pathologic study of 49 tumors. J Cutan Pathol. 1983;10:310–20.
3. Portincasa A, Cecchino L, Trecca EMC, et al. A rare case of Brooke-Spiegler syndrome: integrated surgical treatment of multiple giant eccrine spiradenomas of the head and neck in a young girl. Int J Surg Case Rep. 2018;51:277–81.
4. Ren F, Hu Z, Kong Q, Sang H. Multiple segmental eccrine spiradenoma with a zosteriform pattern: a case report and literature review. Ann Dermatol. 2015;27:435–8.
5. Laurent P, Boullie MC, Thomine E, Stewart WW. Giant eccrine spiradenoma. Ann Dermatol Venereol. 1977;104:485–7.
6. Jamshidi M, Nowak MA, Chiu YT, Perry EA, Fatteh SM. Giant malignant eccrine spiradenoma of the scalp. Dermatol Surg. 1999;25:45–8.
7. Cotton DW, Slater DN, Rooney N, Goepel JR, Mills PM. Giant vascular eccrine spiradenomas: a report of two cases with histology, immunohistology and electron microscopy. Histopathology. 1986;10:1093–9.
8. Aydin G, Balci M, Aydin R. Giant vascular eccrine spiradenoma of the leg: MR imaging findings. Diagn Interv Imaging. 2017;98:89–91.
9. Krishnan K, Thomas A. Giant vascular eccrine spiradenoma with unusual clinical presentation: a case report. Open J Pathol. 2014;4:21–4.
10. Nakamura Y, Teramoto Y, Yamada K, Yamamoto A. Giant vascular eccrine spiradenoma mimicking chronic expanding hematomata. J Dtsch Dermatol Ges. 2014;12:908–10.
11. Yamakoshi T, Makino T, Watanabe H, Furuchi M, Matsui K. A case of giant vascular eccrine spiradenoma with unusual clinical features. Clin Exp Dermatol. 2009;34:e250–1.
12. Kim MH, Cho E, Lee JD, Cho SH. Giant vascular eccrine spiradenoma. Ann Dermatol. 2011;23:197–200.
13. Watanabe S, Hirose M, Sato S, Takahashi H. Immunohistochemical analysis of cytokeratin expression in eccrine spiradenoma: similarities to the transitional portions between sebaceous segments and coiled ducts of eccrine glands. Br J Dermatol. 1994;131:799–807.
14. Ko JY, Lee CW, Moon SH, Song KW, Park CK. Giant vascular eccrine spiradenoma: report of a case with immunohistochemical study. J Korean Med Sci. 2006;21:172–6.
15. Georgesen C, Magro C. Myoepithelial Rich and Infiltrative Giant Vascular Eccrine Spiradenoma: A Unique Presentation of a Rare Adnexal Tumor. A J Dermatopathol. 2018;40:428–32.
16. Eckert F, Betke M, Schmoeckel C, Neuweller J, Schmid U. Myoepithelial differentiation in benign sweat gland tumors. Demonstrated by a monoclonal antibody to alpha-smooth muscle actin. J Cutan Pathol. 1992;19:294–301.
17. Wiley EL, Milchgrub S, Freeman RG, Kim ES. Sweat gland adenomas: immunohistochemical study with emphasis on myoepithelial differentiation. J Cutan Pathol. 1993;20:337–43.
18. Meyehm M, Fischer HP. Spiradenoma and dermal cylindroma: comparative immunohistochemical analysis and histogenetic considerations. Am J Dermatopathol. 1997;19:154–61.
19. Zheng Y, Tian Q, Wang J, et al. Differential diagnosis of eccrine spiradenoma: a case report. Exp Ther Med. 2014;8:1097–101.
20. Englander L, Ermer JJ, McClain D, Amin B, Turner RB. A rare case of multiple segmental eccrine spiradenomas. J Clin Aesthet Dermatol. 2011;4:38–44.
21. Goeette DK, McConnell MA, Fowler VR. Cylindroma and eccrine spiradenoma coexistent in the same lesion. Arch Dermatol. 1982;118:273–4.
22. Michal M, Lamovec J, Mukensnabl P, Pizinger K. Spiradenocylindromas of the skin: tumors with morphological features of spiradenoma and cylindroma in the same lesion: report of 12 cases. Pathol Int. 1999;49:419–25.
23. McAlmont TH. A call for logic in the classification of adnexal neoplasms. Am J Dermatopathol. 1996;18:103–9.
24. Torquera Barquero E, Lara Bohórquez C, de Alba Rioja J. Giant vascular eccrine spiradenoma (inEnglish, Spanish). Actas Dermosifiliogr. 2015;106:850–2.
25. Tremesayguess LL, Pföhler C, Vogt T, Müller CS. Differential considerations of skin tumours with florid vascularisation: report of a solitary giant vascular eccrine spiradenoma. BMJ Case Rep. 2011; 2011.
26. Cukic D, Jovanovic MB, Milutinovic Z. An unusual nodule on the auricle: eccrine spiradenoma. Ear Nose Throat J. 2019;98:545–6.
27. Park HR, Im SB, Kim HK, Shin DS, Park YL. Painful eccrine spiradenoma containing nerve fibers: a case report. Dermatolog. 2012;22:301–6.
28. Park JW, Namkoong S, nChung J, et al. A case of eccrine spiradenoma in a patient with neurofibromatosis. Ann Dermatol. 2010;22:191–3.
29. Hatano A, Kobayashi T, Fukuzumi S, et al. Giant vascular eccrine spiradenoma mimicking calcifying epitheliosis. J Dermatol. 2013;40:853–54.
30. Senol M, Ozcan A, Sasmaz S, Özen S, Cirakil H. Giant vascular eccrine spiradenoma. Int J Dermatol. 1998;37:221–3.
31. Hey A, Grous V, Röckelein G. Vascular eccrine giant spiradenoma--a case report with histology and immunohistology of a rare variant of benign sweat gland tumors. Z Hautkr. 1988;63:444–7.
32. Ishikawa M, Nakanishi Y, Yamamoto N, Yamamoto A. Malignant eccrine spiradenoma: a case report and review of the literature. Dermatol Surg. 2002;27:67–70.
33. Catteau X, Dhæne N, Noël JC. Low grade malignant eccrine spiradenoma of the vulva: case report, review of the literature and discussion about the role of p53 and HPV. Diagn Pathol. 2020;15:24.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions